Research and Markets: Rheumatology Thought Leader Panel - Lupus/Rheumatoid Arthritis - 2012

<0> Research and Markets: Rheumatology Thought Leader Panel - Lupus/Rheumatoid Arthritis - 2012 </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Rheumatology Thought Leader Panel #36 2012-08 captures discussions with 6 internationally recognized experts (4 US, 2 EU) in the treatment of lupus

and rheumatoid arthritis. The two main topics this Panel was asked to address were:

1) What are the most significant therapies in the lupus pipeline?

2) What toxicologies are going to limit the use of oral DMARDs for rheumatoid arthritis?

Lupus nephritis is to rheumatology today what rheumatoid arthritis was in the early 90's. For those too young to remember, most pharmaceutical companies obsessed with the need to commercialize a disease modifying therapy for osteoarthritis; because the patient population, and thus the commercial opportunity, was so much larger than rheumatoid arthritis. Clinically relevant druggable targets for osteoarthritis have been devilishly hard to develop. But the few pharma companies that instead focused on attacking the underlying autoimmune mechanisms produced highly successful franchises that now branch across rheumatoid arthritis, Crohn's/ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis and more. While mild-to-moderate systemic lupus erythematosus is easy to treat, lupus nephritis is associated with high morbidity and mortality. Today osteoarthritis is routinely

and effectively treated with hip, knee and shoulder replacement. Second only to nonsurgical reversal of osteoarthritis, a pharmacotherapy for lupus nephritis is the largest unmet need in the rheumatology space. This is the topic for the first half of Rheum TLP #36.

Executive Summary

Introduction

Report Highlights

- Lupus Discussion

-- Unmet Needs / Diagnosis / Biomarkers

-- BAFF

--- Benlysta (belimumab; HGS / GSK)

--- blisibimod Anthera

--- tabalumab (LY2127399; Lilly)

--- atacicept (Merck-Serono)

-- CTLA4 Agonist

--- Orencia (abatacept / ONO-4164SC / BMS-188667SC; BMS / Ono)

-- CD20

--- Rituxan / MabThera (rituximab; Roche / Biogen)

--- rituximab biosimilars (manufacturers: Celltrion, Teva, Sandoz, Spectrum/Viropro, Pfizer, Merck, Vifor, Dr. Reddy) p47

-- CD22

--- epratuzumab (UCB / Immunomedics)

-- anti-IFN p53

--- sifalimumab MEDI-545 anti-IFN / MedImmune / AstraZeneca

--- rontalizumab rhuMAb IFN / (Genentech)

--- IFN-K (Neovacs)

--- AMG-811 anti-IFN

-- RNP

--- Lupuzor (ImmuPharma)

-- IL6

--- tocilizumab (Roche / Chugai)

-- immunomodulatory

--- laquinimod (Teva)

- Rheumatoid Arthritis / Psoriatic Arthritis Discussion

-- JAK

--- tofacitinib (Pfizer)

--- VX-509 (Vertex)

--- GLPG0634 Galapagos / Abbott

--- baricitinib LY3009104 (INCB28050; Incyte / Lilly)

--- ASP015K (Astellas)

-- Syk

--- fostamatinib (AstraZeneca / Rigel)

--- PRT-062607 (Portola / Biogen)

--- GS-9973 (Gilead)

--- GSK-143 (GlaxoSmithKline)

-- CCR1 / IP10 / CXCR3

--- CCX354-C (GSK / ChemoCentryx)

--- SCH-546738 (Merck)

--- PS372424 (Newcastle)

--- Boehringer-Ingelheim

-- BTK

--- ibrutinib (PCI-32765; Janssen / Pharmacyclics)

--- RN486 (Roche)

--- GDC-0834 (Roche / Genentech / Biogen)

--- AVL-292 (Celgene /Avila)

-- ONO-WG-307 (Ono)

--- TP-0829 (Tolero / MannKind)

-- PDE4

--- apremilast (Celgene)

-- Cathepsin K

--- odanacatib (Merck)

Thought Leader Interviews

- Amgen

- Anthera

- Astellas

- AstraZeneca / Medimmune

- AstraZeneca / Rigel

- Boehringer-Ingelheim

- Bristol-Myers Squibb / Ono

- Celgene

- Celgene /Avila

- Celltrion

- Dr. Reddy

- Galapagos / Abbott

- Gilead

- GSK / ChemoCentryx

- GSK / HGS belimumab Benlysta

- ImmuPharma

- Incyte / Lilly

- Lilly

- Merck

- Merck-Serono

- Neovacs

- Newcastle

- Novartis (Sandoz)

- Ono

- Pfizer

- Pharmacyclics / Janssen

- Portola / Biogen

- Rigel / AstraZeneca

- Roche / Genentech / Chugai

- Roche / Genentech / Biogen

- Spectrum/ Viropro

- Teva

- Tolero / MannKind

- UCB / Immunomedics

- Vertex

- Vifor

For more information visit

Suggested Articles

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.